...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155


BREAKING: Spyder Cannabis Announces Plans to Enter US Hemp Derived Market Through Rollout of Boutique Retail and Kiosk Stores

  • Newly Listed Spyder Cannabis $SPDR.ca Announces Phase 1 plan for locations in 4 states
  • Already an established Ontario retail operator
  • Partnering with developers & realtors for prime real estate high traffic areas (Malls, Sport Venues)

Spdr logo large

Hub On AGORACOM / Read Release

Message: Scenario Analysis on end of BETonMACE Phase 3

iconoclast - I follow this story pretty closely and have never heard that the company gets patient by patient data that would allow them to see the eGFR for each patient. I have heard that they do get bulk information that would allow their scientists to see trends for all patients for which they may be able to make educated guesses.

It won't be long now before we see the Top Line data followed up a number of months later with a full data announcement. I sincerely hope the tundup's words of "stunning and unheard of results" in CKD and cognitive function are true and correct. This could literally mean the world to many patients and of course put a few quid in our pockets.


New Message
Please login to post a reply